Y a beta3 integrin ependent mechanism.

Y a beta3 integrin ependent mechanism. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/12711626 Nat Med. 2002;8(3):247?2. 23. Leveille C, Bouillon M, Guo W, Bolduc J, Sharif-Askari E, El-Fakhry Y, et al. CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling. J Biol Chem. 2007;282(8):5143?1. 24. Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation. 2007;115(12):1571?0. 25. Hassan GS, Merhi Y, Mourad WM. CD154 and its receptors in inflammatory vascular pathologies. Trends Immunol. 2009;30(4):165?2. 26. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995;25(6):1749?4. 27. Peitsch MC, Jongeneel CV. A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int Immunol. 1993;5(2):233?.Dewitte et al. Experimental Hematology Oncology (2015) 4:Page 9 of28. Fanslow WC, Srinivasan S, Paxton R, Gibson MG, Spriggs MK, Armitage RJ. Structural characteristics of CD40 ligand that determine biological function. Semin Immunol. 1994;6(5):267?8. 29. Karpusas M, Hsu YM, Wang JH, Thompson J, Lederman S, Chess L, et al. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure. 1995;3(10):1031?. Methyl 4-chloro-5-fluoroanthranilate 30. Pietravalle F, Lecoanet-Henchoz S, Blasey H, Aubry JP, Elson G, Edgerton MD, et al. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem. 1996;271(11):5965?. 31. Bishop GA, Moore CR, Xie P, Stunz LL, Kraus ZJ. TRAF proteins in CD40 signaling. Adv Exp Med Biol. 2007;597:131?1. 32. Donners MM, Beckers L, Lievens D, Munnix I, Heemskerk J, Janssen BJ, et al. The CD40-TRAF6 axis is the journal.pone.0167038 key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood. 2008;111(9):4596?04. 33. Chatzigeorgiou A, Seijkens T, Zarzycka B, Engel D, Poggi M, van den Berg S, et al. Blocking CD40-TRAF6 signaling is a therapeutic target in obesityassociated insulin resistance. Proc Natl Acad Sci U S A. 2014;111(7):2686?1. 34. Horrillo A, Fontela T, Arias-Salgado EG, Llobat D, Porras G, Ayuso MS, et al. Generation of mice with conditional ablation of the Cd40lg Tert-butyl 2-(chloromethyl)pyrrolidine-1-carboxylate gene: new insights on the role of CD40L. Transgenic Res. 2014;23(1):53?6. 35. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391(6667):591?. 36. Kamykowski J, Carlton P, Sehgal S, Storrie B. Quantitative immunofluorescence mapping reveals little functional coclustering of proteins within platelet alpha-granules. Blood. 2011;118(5):1370?. 37. Charafeddine AH, Kim EJ, Maynard DM, Yi H, Weaver TA, Gunay-Aygun M, et al. Platelet-derived CD154: ultrastructural localization and clinical correlation in organ transplantation. Am J Transplant. 2012;12(11):3143?1. 38. Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand (CD40L) ubcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets. 2001;12(2):74?2. 39. Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/22763976 anucleate platelets. Cell. 2005;122(3):379?1. 40. Rowley JW, Schwertz H, Weyrich AS. Platelet mRNA: the meaning behind the message. Curr Opin Hematol. 2012;19(5):385?1. 41. Ree.